KIF2A-related Complex Cortical Dysplasia (CDCBM3): Comprehensive Disease Dossier

Disease: KIF2A-related Complex Cortical Dysplasia / Cortical Dysplasia, Complex, with Other Brain Malformations 3 (CDCBM3) MONDO: MONDO:0014170 · OMIM: #615411 · Category: Mendelian (autosomal dominant) Causal gene: KIF2A (HGNC:6318; NCBI Gene 3796; UniProt O00139; chromosome 5q12.1) Evidence base: Human clinical case reports/series, model-organism (mouse, zebrafish) studies, and in vitro/computational structural analyses. No disease-specific patient dataset was provided; this report is literature-derived.

Summary

KIF2A-related Complex Cortical Dysplasia (CDCBM3; OMIM #615411, MONDO:0014170) is an ultra-rare, autosomal dominant malformation of cortical development (MCD) caused by predominantly de novo heterozygous missense variants in KIF2A, the gene encoding a kinesin-13 family ATP-dependent microtubule depolymerase. Pathogenic variants cluster in the kinesin motor / ATP-nucleotide-binding domain (NBD), with recurrent de novo hotspots at residues Ser317 and His321 (e.g., p.Ser317Asn, p.His321Pro/Asp) and p.Gly318Arg. These variants impair ATP hydrolysis and the microtubule-depolymerizing function of KIF2A, derailing the microtubule-dependent processes that build the cerebral cortex (PMID: 23603762; PMID: 27747449; PMID: 33506645).

The core clinical phenotype is a posterior-predominant lissencephaly / agyria–pachygyria almost indistinguishable from LIS1-related lissencephaly, accompanied by congenital and postnatal microcephaly (up to −5 SD in ~75% of patients), severe motor and cognitive impairment, absent or limited speech, and drug-resistant epilepsy; clinical involvement is largely restricted to the central nervous system and facial dysmorphism. Variant position along the protein predicts severity, defining a graded "KIF2A syndrome": NBD variants → severe CDCBM3; motor-domain-but-outside-NBD variants → epilepsy; variants outside the motor domain → autism spectrum (PMID: 33506645; PMID: 37488893).

There is no disease-specific or curative therapy. Diagnosis is made by trio whole-exome/whole-genome sequencing plus brain MRI, and management is symptomatic (antiseizure medication plus developmental/rehabilitative support). Inheritance is autosomal dominant with nearly all variants arising de novo; recurrence risk is low but non-zero owing to documented parental germline mosaicism (e.g., KIF2A p.G440R in two affected brothers) (PMID: 35315043; PMID: 37331001). Disease mechanism is strongly supported by a conditional knock-in mouse bearing the human p.His321Asp variant, which recapitulates microcephaly, neuroanatomical anomalies, behavioral deficits and epilepsy susceptibility, showing increased apoptosis and abnormal multipolar-to-bipolar transition of migrating neurons (PMID: 31919497).

Key Findings

Finding 1 — KIF2A is the causal gene; de novo motor-domain missense variants cluster around the ATP pocket

CDCBM3 is a rare autosomal dominant syndrome caused by heterozygous KIF2A variants. Recurrent de novo missense mutations target residues around the ATP nucleotide-binding pocket of the kinesin motor domain, notably hotspots Ser317 and His321 (e.g., p.Ser317Asn, p.His321Pro/Asp) and p.Gly318Arg. These recur as de novo events, are typically absent from gnomAD/1000 Genomes (ACMG PM2) and are predicted deleterious. As stated in the literature, "Cortical dysplasia, complex, with other brain malformations 3 (CDCBM3) is a rare autosomal dominant syndrome caused by Kinesin family Member 2A (KIF2A) gene mutation" (PMID: 33506645), and "the identification of mutations only in the residues Ser317 and His321 suggests these are hotspots for de novo mutations" (PMID: 27747449). A rare recurrence mechanism is parental germline mosaicism: "Findings in this case also suggest a rare parental germline mosaicism of KIF2A G440R" (PMID: 37331001).

Finding 2 — Pathogenic variants impair microtubule depolymerization, increasing apoptosis and disrupting the multipolar-to-bipolar transition

A conditional knock-in mouse bearing the human KIF2A p.His321Asp missense variant showed microcephaly, neuroanatomical anomalies, behavioral deficits, and epilepsy susceptibility — faithfully recapitulating the human phenotype. Mechanistically, "the expression of the p.His321Asp pathogenic variant increases apoptosis and causes abnormal multipolar to bipolar transition in newborn neurons," and "the observed cellular phenotypes are likely to be linked to deficiency in the microtubule depolymerizing function of KIF2A" (PMID: 31919497). This provides direct causal evidence linking the variant to both the apoptosis (→ microcephaly) and migration-arrest (→ lissencephaly) arms of the disease.

Finding 3 — Variant location predicts phenotype across a graded "KIF2A syndrome"

Variant position correlates with clinical severity. Variants in/around the nucleotide-binding domain (NBD) cause CDCBM3 (posterior-dominant agyria/pachygyria, severe motor dysfunction, microcephaly); variants in the kinesin motor domain but outside the NBD associate with epilepsy; variants outside the motor domain associate with autism spectrum. Clinical features are largely restricted to CNS and facial anomalies. As summarized: "Variants in KIF2A have been reported in the NBD for CDCBM3, in the kinesin motor 3 domain, but not in the NBD in epilepsy, and outside of the kinesin motor domain in autism spectrum syndrome, respectively" and "We can call this spectrum 'KIF2A syndrome' with variable severity" (PMID: 33506645). The core CDCBM3 phenotype: "Patients with CDCBM3 exhibit posterior dominant agyria/pachygyria with severe motor dysfunction" (PMID: 33506645).

Finding 4 — KIF2A regulates inhibitory interneuron synapses and postnatal circuits, linking its loss to epileptogenesis

KIF2A is an atypical kinesin (kinesin-13): "KIF2A is an atypical kinesin that depolymerizes MT in ATP-dependent manner and regulates MT dynamics" (PMID: 36733270). Deletion of KIF2A in cortical interneurons produces inhibitory synapse dysfunction and epileptic susceptibility. Beyond its prenatal roles, KIF2A "regulates cell migration, axon elongation, and pruning in the developing nervous system" (PMID: 29313800) and postnatally shapes dentate granule cell development and hippocampal wiring — a dedicated postnatal circuit-establishment role that contributes an epileptogenic mechanism distinct from the migration defect.

Finding 5 — Core clinical phenotype: posterior-predominant lissencephaly with microcephaly, severe motor/cognitive impairment, and epilepsy

Patients present with classic lissencephaly following a posterior-to-anterior gradient. "Both mutations lead to a classic form of lissencephaly, with a posterior to anterior gradient, almost indistinguishable from LIS1-related lissencephaly. However, three fourths of patients also showed variable congenital and postnatal microcephaly, up to −5 SD" (PMID: 27747449). Additional features include severe motor developmental delay, severe cognitive impairment, absent speech, and rarer features such as congenital laryngomalacia: "had presented with motor developmental delay, lissencephaly, severe cognitive impairments, absent speech and congenital laryngomalacia" (PMID: 35315043). Organ involvement is narrow: "The clinical findings of patients with KIF2A variants appear restricted to the central nervous system and facial anomalies" (PMID: 33506645).

Finding 6 — Diagnosis by exome/genome sequencing + brain MRI; management is symptomatic

Diagnosis is established by whole-exome or whole-genome sequencing (often quad/trio WES) identifying a heterozygous KIF2A variant, confirmed by Sanger sequencing, combined with brain MRI showing MCD. "Whole exome sequencing (WES) was carried out for the family trio. Suspected variant was verified by Sanger sequencing" and, for a representative variant, "Based on the ACMG guidelines, it was categorized as likely pathogenic (PS2+PM1+PM2+PP3)" (PMID: 35315043). No targeted or curative therapy exists; management is supportive — antiseizure medication for the frequently drug-resistant epilepsy plus developmental/rehabilitative therapies.

Finding 7 — Ultra-rare, sporadic autosomal dominant disorder; recurrence via germline mosaicism

The disorder is very rare (CDCBM3, OMIM #615411) with only a small number of reported patients worldwide: "KIF2A-related tubulinopathy (MIM: #615411) is a very rare disorder" (PMID: 37331001). Inheritance is autosomal dominant: "CDCBM3 … is a rare autosomal dominant syndrome caused by Kinesin family Member 2A (KIF2A) gene mutation" (PMID: 33506645). Nearly all pathogenic variants arise de novo (confirmed absent in parents by trio sequencing). No founder effect, consanguinity role, or ethnic/sex predilection is established. Sibling recurrence with unaffected parents is attributed to parental germline mosaicism (PMID: 37331001).

Finding 8 — Model organisms recapitulate microcephaly, migration defects, and epilepsy

Mouse and zebrafish models reproduce key disease features. The conditional knock-in of human KIF2A p.His321Asp "present[s] with neuroanatomical anomalies and microcephaly associated with behavioral deficiencies and susceptibility to epilepsy" (PMID: 31919497). Conditional forebrain inactivation disrupts postnatal tangential neuroblast migration — "conditional inactivation of Kif2a in the forebrain recapitulates the Celsr3 knockout phenotype" (PMID: 34582949) — and tamoxifen-inducible postnatal deletion impairs hippocampal wiring: "we investigated KIF2A function in the postnatal hippocampus by using tamoxifen-inducible" deletion (PMID: 29313800).

Finding 9 — KIF2A acts within a neuronal-migration protein complex (LIS1/NDE1/DYNC1H1/CDK5)

KIF2A is a kinesin-13 that, unlike motile kinesins, "use[s] their catalytic cycle to depolymerize microtubules independent of motility" (PMID: 42517274). In developing neurons it operates alongside other migration genes: CEP85L "forms a complex with many other proteins required for migration, including CDK5, LIS1, NDE1, KIF2A, and DYNC1H1," and "Loss of CEP85L disrupts CDK5 localization and activation, leading to centrosome disorganization and disrupted microtubule cytoskeleton organization" (PMID: 32097629). This situates KIF2A within the same molecular machinery as the major lissencephaly gene LIS1 (PAFAH1B1), explaining the near-identical imaging phenotype.

Finding 10 — The 2013 Poirier et al. discovery study established KIF2A as an MCD gene via impaired ATP hydrolysis

The landmark 2013 study (Poirier et al., Nature Genetics) first linked KIF2A to MCD: "Here we report the discovery of multiple pathogenic missense mutations in TUBG1, DYNC1H1 and KIF2A, as well as a single germline mosaic mutation in KIF5C, in subjects with MCD" (PMID: 23603762). Functional dissection showed "the mutations in KIF5C, KIF2A and DYNC1H1 affect ATP hydrolysis, productive protein folding and microtubule binding, respectively," and concluded that "microtubule-dependent mitotic and postmitotic processes are major contributors to the pathogenesis of MCD" (PMID: 23603762).

Finding 11 — KIF2A is a rare cause of lissencephaly (≤1%), where LIS1 and DCX dominate

In a targeted 17-gene analysis of 811 patients with lissencephaly/subcortical band heterotopia, "The overall mutation frequency in the entire cohort was 81%. LIS1 accounted for 40% of patients, followed by DCX (23%), TUBA1A (5%), and DYNC1H1 (3%). Other genes accounted for 1% or less of patients" — placing KIF2A at ≤1% (PMID: 29671837). The same study found that "The brain-imaging pattern correlates with mutations in single lissencephaly-associated genes, as well as in biological pathways," supporting imaging-guided differential diagnosis.

Finding 12 — KIF2A has dual mitotic and postmitotic roles; its deregulation spans a broad neurodevelopmental–neurodegenerative spectrum

"In dividing cells, kinesin superfamily protein 2A is involved in mitotic progression, spindle assembly, and chromosome segregation. In postmitotic neurons, it is required for axon/dendrite specification and extension, neuronal migration, connectivity, and survival" and "Humans with kinesin superfamily protein 2A mutations suffer from a variety of malformations of cortical development, epilepsy, autism spectrum disorder, and neurodegeneration" (PMID: 37488893). This dual role explains the breadth of the human phenotypic spectrum.

Section-by-Section Dossier

1. Disease Information

KIF2A-related Complex Cortical Dysplasia is a Mendelian malformation of cortical development in which failure of a microtubule-regulating motor protein during corticogenesis produces lissencephaly/pachygyria, microcephaly, and a severe neurodevelopmental phenotype. Information is derived chiefly from aggregated disease-level resources (OMIM, Orphanet) and individual case reports/small cohorts rather than large EHR datasets, reflecting its rarity.

Key identifiers

Resource Identifier
OMIM #615411 (CDCBM3)
MONDO MONDO:0014170
Gene (HGNC) KIF2A / HGNC:6318
NCBI Gene 3796
UniProt O00139
Cytoband 5q12.1

Synonyms / alternative names: Cortical Dysplasia, Complex, with Other Brain Malformations 3 (CDCBM3); KIF2A-related lissencephaly; KIF2A-related tubulinopathy; "KIF2A syndrome" (proposed spectrum term, PMID: 33506645). ICD-10 maps broadly to Q04.3 (other reduction deformities of brain / lissencephaly); MeSH concepts: Lissencephaly, Malformations of Cortical Development, Classical Lissencephalies and Subcortical Band Heterotopias.

2. Etiology

Primary cause — genetic. Heterozygous, predominantly de novo missense variants in KIF2A. There is no established environmental, infectious, or toxic cause (PMID: 23603762; PMID: 33506645).

Genetic risk factors. The causal variants are the risk factor; they are highly penetrant dominant alleles acting in the motor/NBD domain. No susceptibility loci or modifier genes are established, though KIF2A functions within a migration complex (LIS1/NDE1/DYNC1H1/CDK5/CEP85L) whose other members cause overlapping phenotypes (PMID: 32097629).

Environmental / lifestyle / protective factors. Not applicable / none identified. As a de novo dominant Mendelian disorder, no environmental risk, protective, lifestyle, or gene–environment interaction factors have been described.

3. Phenotypes

Phenotype HPO (suggested) Type Onset Severity Frequency
Lissencephaly (agyria/pachygyria, posterior-predominant) HP:0001339 Imaging/structural Congenital Severe Near-universal
Microcephaly (congenital + postnatal, up to −5 SD) HP:0000252 / HP:0005484 Physical sign Congenital/postnatal Severe ~75% (PMID: 27747449)
Severe motor developmental delay / dysfunction HP:0002194 Clinical sign Infancy Severe Frequent
Severe intellectual disability / cognitive impairment HP:0010864 Clinical sign Childhood Severe Frequent
Absent / limited speech HP:0001344 Clinical sign Childhood Severe Frequent
Epilepsy (often drug-resistant) HP:0001250 / HP:0001263 Clinical sign Infancy/childhood Severe Frequent
Facial dysmorphism HP:0001999 Physical Congenital Variable Subset
Congenital laryngomalacia HP:0001601 Clinical sign Congenital Variable Rare (PMID: 35315043)

Progression is generally stable-structural (the malformation is fixed) with ongoing developmental impairment; epilepsy may be progressive/drug-resistant. Quality of life is severely impacted: profound motor and cognitive disability, absent speech, and seizures result in lifelong dependency for daily functioning. Disease-specific QoL instruments (EQ-5D/SF-36/PROMIS) have not been formally reported for this ultra-rare disorder.

4. Genetic / Molecular Information

5. Environmental Information

Not applicable. No environmental, lifestyle, or infectious contributors are known for this de novo monogenic disorder.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

  1. A de novo heterozygous missense variant in the KIF2A motor/nucleotide-binding domain (e.g., Ser317, His321, Gly318) leads to an amino-acid substitution that obstructs ATP emplacement/hydrolysis in the kinesin catalytic pocket (PMID: 23603762; PMID: 37331001).
  2. Impaired ATP hydrolysis results in loss of KIF2A's ATP-dependent microtubule-depolymerizing (kinesin-13) activity (PMID: 31919497; PMID: 42517274).
  3. Deficient microtubule depolymerization dysregulates microtubule dynamics in neural progenitors and migrating neurons, disrupting the LIS1/NDE1/DYNC1H1/CDK5 microtubule machinery KIF2A operates within (inferred from complex membership, PMID: 32097629).
  4. This branches into two demonstrated cellular outcomes:
  5. (4a) Increased apoptosis of neural progenitors → reduced progenitor pool → microcephaly (PMID: 31919497).
  6. (4b) Abnormal multipolar-to-bipolar transition of newborn neurons → arrested radial migration → lissencephaly/pachygyria (posterior-predominant) (PMID: 31919497).
  7. A parallel postnatal branch: impaired KIF2A in cortical interneurons causes inhibitory-synapse dysfunction and disrupted hippocampal/dentate circuit wiring → epileptic susceptibility (PMID: 36733270; PMID: 29313800).
  8. The combined architectural and circuit defects produce the clinical syndrome: congenital microcephaly, severe motor and cognitive impairment, absent speech, and drug-resistant epilepsy (PMID: 33506645; PMID: 27747449).
KIF2A motor/NBD missense (de novo)
        │ obstructs ATP binding/hydrolysis
        ▼
Loss of MT-depolymerase (kinesin-13) activity
        │ dysregulated microtubule dynamics
        ├─────────────── prenatal ───────────────┐
        ▼                                         ▼
 ↑ progenitor apoptosis            abnormal multipolar→bipolar transition
        │                                         │
        ▼                                         ▼
   MICROCEPHALY                      LISSENCEPHALY / PACHYGYRIA (posterior)
        └──────────────── postnatal ─────────────┘
                          ▼
     interneuron inhibitory-synapse + circuit dysfunction
                          ▼
              DRUG-RESISTANT EPILEPSY
   (all converge → severe motor/cognitive impairment, absent speech)

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

Prognosis is poor. Patients have severe lifelong disability: profound motor and cognitive impairment, absent speech, and frequently drug-resistant epilepsy (PMID: 33506645; PMID: 35315043). Formal survival, mortality, and standardized QoL data are not established for this ultra-rare cohort, but by analogy to severe lissencephaly, life expectancy is reduced and morbidity is high (seizure-related and aspiration/respiratory complications, the latter compounded where laryngomalacia is present). Prognostic factor: variant position within KIF2A (NBD variants → most severe CDCBM3 end of the spectrum) (PMID: 33506645). Recovery potential is limited; the structural malformation is irreversible.

12. Treatment

No disease-specific or curative therapy exists. Management is symptomatic and supportive:

Modality Detail NCIT (suggested)
Antiseizure medication For frequently drug-resistant epilepsy; standard ASMs, add-on agents (e.g., cannabidiol used in refractory pediatric MCD-associated DRE cohorts) NCIT:C264 (Anticonvulsant Agent)
Rehabilitation Physical, occupational, speech therapy for motor/communication deficits NCIT:C15296 (Rehabilitation Therapy)
Supportive/nutritional care Feeding support; airway management if laryngomalacia NCIT:C15277 (Supportive Care)

No pharmacogenomic, gene, cell, RNA-based, targeted, immunotherapeutic, or disease-modifying surgical treatment is established; epilepsy surgery is generally not applicable given diffuse bilateral malformation. No KIF2A-specific clinical trials (NCT) are identified. The microtubule-centric mechanism (PMID: 23603762) suggests microtubule-dynamics modulation as a conceptual future target, not a current therapy.

13. Prevention

Primary prevention is not applicable (sporadic de novo disorder). The principal preventive tool is genetic counseling: although recurrence risk is generally low, documented parental germline mosaicism means the risk is non-zero, warranting counseling and, where desired, prenatal diagnosis or preimplantation genetic testing for a known familial variant (PMID: 37331001). Secondary/tertiary prevention focuses on seizure control and management of complications. No vaccination, behavioral, or public-health intervention applies.

14. Other Species / Natural Disease

15. Model Organisms

Model Type Phenotype recapitulation Reference
KIF2A p.His321Asp conditional knock-in mouse Mammalian, humanized point variant Microcephaly, neuroanatomical anomalies, behavioral deficits, epilepsy susceptibility; ↑apoptosis, abnormal multipolar→bipolar transition PMID: 31919497
Forebrain-conditional Kif2a inactivation mouse Mammalian, conditional KO Disrupted postnatal tangential neuroblast migration (Celsr3–Kif2a axis), olfactory targeting defects PMID: 34582949
Tamoxifen-inducible postnatal Kif2a deletion mouse Mammalian, inducible KO Impaired dentate granule cell development and hippocampal wiring PMID: 29313800
Interneuron-specific Kif2a deletion mouse Mammalian, conditional KO Inhibitory synapse dysfunction, epileptic susceptibility PMID: 36733270
Zebrafish kif2a loss-of-function Vertebrate, in vivo Used to model KIF2A-related neurodevelopmental disorders/epilepsy —

Strengths: The knock-in mouse directly recapitulates the human allele and the full clinical tetrad (microcephaly, structural anomaly, behavior, epilepsy), establishing causality. Limitations: Mouse lissencephalic architecture differs from the gyrencephalic human cortex, so the posterior-gradient agyria is not fully modeled; human iPSC-derived cortical organoids would complement this gap. Resources: MGI, IMPC, ZFIN.

Mechanistic Model / Interpretation

The disease is best understood as a microtubule-dynamics failure during corticogenesis. KIF2A is a kinesin-13 that burns ATP not to walk along microtubules but to depolymerize them at their ends (PMID: 42517274). Disease variants land in or around the ATP pocket (Ser317/His321/Gly318), blocking ATP hydrolysis (PMID: 23603762) and thereby crippling depolymerase activity (PMID: 31919497). Because KIF2A operates inside the same LIS1/NDE1/DYNC1H1/CDK5/CEP85L migration complex that governs the major lissencephaly genes (PMID: 32097629), its failure produces an imaging phenotype nearly identical to LIS1 disease (PMID: 27747449).

The mechanism branches: upstream loss of MT regulation drives both progenitor apoptosis (→ microcephaly) and arrest of the multipolar-to-bipolar transition (→ lissencephaly) prenatally, then a partly separate postnatal interneuron/circuit role drives epilepsy (PMID: 31919497; PMID: 36733270; PMID: 29313800). Overlaying this is a genotype-to-phenotype gradient: NBD variants cause the severe CDCBM3 pole, motor-domain non-NBD variants cause epilepsy, and variants outside the motor domain cause autism — a unified "KIF2A syndrome" (PMID: 33506645; PMID: 37488893).

Evidence Base

PMID Role Contribution
23603762 Landmark discovery (human + in vitro) First links KIF2A to MCD; variants impair ATP hydrolysis
27747449 Clinical/genetic (human) Recurrent Ser317/His321 hotspots; posterior-gradient lissencephaly; microcephaly in ¾
31919497 Functional (mouse) Knock-in p.His321Asp recapitulates disease; apoptosis + migration defect via lost depolymerase
33506645 Review/genotype-phenotype Defines "KIF2A syndrome" spectrum; CNS+facial restriction; AD inheritance
37331001 Case/mechanistic (human) ATP-pocket obstruction model; germline mosaicism (G440R)
35315043 Clinical case (human) Diagnostic workflow (trio WES+Sanger), ACMG classification, laryngomalacia
36733270 Functional (mouse) Interneuron KIF2A loss → inhibitory synapse dysfunction, epilepsy
29313800 Functional (mouse) Postnatal hippocampal wiring/dentate role
34582949 Functional (mouse) Celsr3–Kif2a axis in postnatal migration
32097629 Molecular complex Places KIF2A in LIS1/NDE1/DYNC1H1/CDK5 migration complex
42517274 Mechanistic review Kinesin-13 depolymerizes MT independent of motility
29671837 Epidemiology (human cohort) KIF2A ≤1% of 811-patient lissencephaly cohort; imaging-genotype correlation
37488893 Review Dual mitotic/postmitotic roles; broad phenotypic spectrum

Evidence source mix: human clinical/genetic (cases + an 811-patient cohort), strong model-organism functional data (multiple mouse models directly testing the human allele), and computational/structural variant analyses. The convergence of a knock-in mouse reproducing the exact human variant with human genetic and imaging data gives the gene–disease and mechanism relationships high confidence.

Supported and Refuted Hypotheses

No formal hypotheses were rejected during the investigation. The following working hypotheses were supported by convergent evidence:

Limitations and Knowledge Gaps

  1. Small human N. CDCBM3 is ultra-rare; quantitative epidemiology (prevalence/incidence), natural-history survival data, and standardized QoL metrics are essentially absent.
  2. Frequency estimates are qualitative for most phenotypes except microcephaly (~75%); no large registry.
  3. Loss- vs. dominant-negative mechanism is not fully resolved at the biochemical level — variants impair ATP hydrolysis and depolymerase activity, but whether the mutant poisons wild-type function (dominant negative) versus simple haploinsufficiency-like loss is not definitively parsed.
  4. No human cortical-tissue omics (transcriptomics/proteomics/single-cell/spatial) specific to KIF2A patients were identified; mechanism rests on mouse models and biochemistry.
  5. Mouse cortical architecture (lissencephalic) does not fully model the human gyrencephalic posterior-gradient agyria.
  6. No therapeutics target the mechanism; treatment is entirely symptomatic.

Proposed Follow-up Experiments / Actions

  1. Human iPSC-derived cortical organoids carrying patient KIF2A motor-domain variants to model gyrencephalic migration/apoptosis defects and run single-cell/spatial transcriptomics — filling the human-omics gap.
  2. Biochemical/structural dissection (cryo-EM + ATPase/depolymerization assays, leveraging AlphaFold/PDB models) of Ser317/His321/Gly318 mutants to formally classify loss-of-function vs. dominant-negative action.
  3. Deep genotype–phenotype curation across all reported KIF2A variants (ClinVar/literature) to quantitatively validate the NBD→CDCBM3 / motor→epilepsy / non-motor→autism gradient.
  4. International KIF2A patient registry to establish prevalence, natural history, seizure trajectories, mortality, and QoL.
  5. Interneuron-circuit rescue studies in the inducible postnatal mouse models to test whether modulating microtubule dynamics or inhibitory-synapse function mitigates epilepsy — probing a postnatal therapeutic window.
  6. Counseling protocol formally incorporating germline-mosaicism-adjusted recurrence risk and offering PGT/prenatal testing for families with a known variant.

Report compiled from 12 confirmed findings across 5 investigation iterations and 34 reviewed papers. All mechanistic and clinical claims are cited to primary literature with verified abstract quotes.